| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/12/2001 | WO2001049702A1 Epididymal antimicrobial peptides |
| 07/12/2001 | WO2001049691A1 CAMPTOTHECIN β-ALANINE ESTERS WITH TOPOISOMERASE I INIBHITION |
| 07/12/2001 | WO2001049325A2 Gene therapy to promote angiogenesis and/or the treatment of heart failure |
| 07/12/2001 | WO2001049324A2 Novel colloid synthetic vectors for gene therapy |
| 07/12/2001 | WO2001049318A1 Novel chimeric proteins and methods for using the same |
| 07/12/2001 | WO2001049316A2 Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization |
| 07/12/2001 | WO2001049315A1 Combination therapy for the treatment of inflammatory and respiratory diseases |
| 07/12/2001 | WO2001049314A2 Glp-2 formulations |
| 07/12/2001 | WO2001049313A1 Use of ngf for the manufacturing of a drug for treating allergic disorders |
| 07/12/2001 | WO2001049312A2 O-superfamily conotoxin peptides |
| 07/12/2001 | WO2001049311A1 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
| 07/12/2001 | WO2001049310A1 C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer |
| 07/12/2001 | WO2001049309A2 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue |
| 07/12/2001 | WO2001049298A2 Novel therapeutic use of enoxaparin |
| 07/12/2001 | WO2001049295A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 07/12/2001 | WO2001049284A1 Composition for stabilizing and potentiating the action of anti-angiogenic substances by polyunsaturated fatty acids |
| 07/12/2001 | WO2001049275A2 Methods and compositions for mitigating pain using nitrate esters |
| 07/12/2001 | WO2001049274A2 Methods for pulmonary delivery of interleukin-2 |
| 07/12/2001 | WO2001049268A1 Pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| 07/12/2001 | WO2001049264A2 Pharmaceutical compositions for oral administration |
| 07/12/2001 | WO2001049260A2 Y-ifn liquid-droplet aerosol and method |
| 07/12/2001 | WO2001049255A2 Methods and compositions for inhibiting adhesion by microorganisms |
| 07/12/2001 | WO2001049249A2 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| 07/12/2001 | WO2001049163A1 Pp14 fusion proteins and methods for making and using the same |
| 07/12/2001 | WO2001049107A1 Animal models for neurodegenerative disease |
| 07/12/2001 | WO2001027096A9 Aminomethyl-(hetero)aryl derivatives and their use as tryptase inhibitors |
| 07/12/2001 | WO2001023562A9 Osteoprotegerin regulatory region |
| 07/12/2001 | WO2001012665A3 Helical cytokine zalpha48 |
| 07/12/2001 | WO2001012650A3 Use of colostrinin, constituent peptides thereof, and analogs thereof as oxidative stress regulators |
| 07/12/2001 | WO2001008677A8 Methods of inhibiting osteoclast activity |
| 07/12/2001 | WO2001004281A3 Dna coding for beta-tubulin and use thereof |
| 07/12/2001 | WO2001002425A3 Peptide conjugates for the stabilization of membrane proteins and interactions with biological membranes |
| 07/12/2001 | WO2001002358A3 Cyclized amide derivatives for treating or preventing neuronal damage |
| 07/12/2001 | WO2001000657A3 Novel indole peptidomimetics as thrombin receptor antagonists |
| 07/12/2001 | WO2001000220A3 Lipoprotein lipase (lpl) variant therapeutics |
| 07/12/2001 | WO2000078333A3 Synergetic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependant diabetes |
| 07/12/2001 | WO2000077034A3 Amino acids from fish and soy proteins improve insulin sensitivity |
| 07/12/2001 | WO2000076456A3 Modulators of fibrosis |
| 07/12/2001 | WO2000075321A3 Polynucleotides and membrane-bound polypeptide encoded thereby |
| 07/12/2001 | WO2000075278A9 Gene encoding nade, p75ntr-associated cell death executor and uses thereof |
| 07/12/2001 | WO2000074724A3 Conjugates comprising cytokines and nucleic acids for treating proliferating cells |
| 07/12/2001 | WO2000062790A3 Soluble tumor necrosis factor receptor treatment of medical disorders |
| 07/12/2001 | WO2000061230A3 Estrogen receptors-beta antagonism and bone diseases |
| 07/12/2001 | WO2000056144A9 Human sperm surface antigen |
| 07/12/2001 | WO2000055318A8 Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 07/12/2001 | WO2000034447A8 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 07/12/2001 | WO2000032750A9 Transgenic circulating endothelial cells |
| 07/12/2001 | WO2000004041A3 Methods and molecules relating to cd39-like polypeptides |
| 07/12/2001 | WO2000000510A3 Growth factor modulators |
| 07/12/2001 | WO1999066031A3 Pharmaceutical factor vii preparation |
| 07/12/2001 | WO1999052541A3 Artery- and vein-specific proteins and uses therefor |
| 07/12/2001 | US20010008025 Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| 07/12/2001 | US20010007902 An oligonucleotide complementary to a region of the ribonucleotide component of telomerase attached to an activator of ribonuclease L (activator-antisense complex) which cleaves ribonuclotide portion of telomerase enzyme |
| 07/12/2001 | US20010007858 Stable mixture |
| 07/12/2001 | US20010007857 Method for treating feline immunodefiency virus infections |
| 07/12/2001 | US20010007855 Antitumor drug |
| 07/12/2001 | US20010007853 By inhalation |
| 07/12/2001 | US20010007767 Genetic engineering |
| 07/12/2001 | US20010007764 Oligopeptides |
| 07/12/2001 | US20010007758 Administering mixture of synthetic polypeptides |
| 07/12/2001 | US20010007757 Genetic engineering |
| 07/12/2001 | US20010007756 Cosmetic compositions |
| 07/12/2001 | US20010007755 Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
| 07/12/2001 | US20010007752 Genetic engineering; nucleic acids |
| 07/12/2001 | US20010007745 Genetic engineering |
| 07/12/2001 | US20010007674 Stimulate hair growth |
| 07/12/2001 | US20010007665 Respiratory system |
| 07/12/2001 | US20010007662 Aqueous formulation suitable for lyophilization; biologically active form of nerve growth factor with bulking agent, buffer and water |
| 07/12/2001 | US20010007661 Or mutein or salt thereof, for treating or preventing Sjogren's syndrome |
| 07/12/2001 | US20010007659 Use of lentiviral vectors for antigen presentation in dendritic cells |
| 07/12/2001 | US20010007657 Providing compound that binds to epidermal growth factor receptor in order to attract glial progenitor cells (or progeny) to site in central nervous system in need of repair |
| 07/12/2001 | US20010007656 Introducing cells treated in vivo with DNA segment comprising transcription factor gene (c-Myc) and operably linked promoter sequence to patient |
| 07/12/2001 | DE19963859A1 Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen Bi- or oligomer of a di-, tri-, Quattro or pentamer of recombinant fusion proteins |
| 07/12/2001 | DE19963612A1 New potassium channel subunit proteins, useful for identifying and testing potential pharmaceuticals, e.g. anti-arrhythmic or neurological agents |
| 07/12/2001 | DE19961899A1 Interaktikonsproteine für STAT Transkriptionsfaktor Interaktikonsproteine for STAT transcription factor |
| 07/12/2001 | DE10000493A1 New condensation products of proteins or protein hydrolysates with azelaic acid, are anionic emulsifiers useful in treatment of inflammation and acne and for skin whitening |
| 07/12/2001 | CA2397714A1 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent |
| 07/12/2001 | CA2396779A1 Gene therapy to promote angiogenesis and/or the treatment of heart failure |
| 07/12/2001 | CA2396529A1 O-superfamily conotoxin peptides |
| 07/12/2001 | CA2396401A1 Novel fgf homolog zfgf12 |
| 07/12/2001 | CA2396399A1 Methods for protein transfer |
| 07/12/2001 | CA2396393A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 07/12/2001 | CA2396379A1 Pharmaceutical compositions for oral administration |
| 07/12/2001 | CA2396364A1 Epididymal antimicrobial peptides |
| 07/12/2001 | CA2396178A1 Novel therapeutic use of enoxaparin |
| 07/12/2001 | CA2396149A1 Transduction of recombinases for inducible gene targeting |
| 07/12/2001 | CA2396114A1 Methods of modulation of the immune system |
| 07/12/2001 | CA2396068A1 Antisense antibacterial cell division composition and method |
| 07/12/2001 | CA2396040A1 Novel bacterial genes and proteins that are essential for cell viability and their uses |
| 07/12/2001 | CA2396037A1 Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix |
| 07/12/2001 | CA2396036A1 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| 07/12/2001 | CA2395945A1 Novel chimeric proteins and methods for using the same |
| 07/12/2001 | CA2395892A1 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release |
| 07/12/2001 | CA2395887A1 Methods for pulmonary delivery of interleukin-2 |
| 07/12/2001 | CA2395876A1 Nucleic acids encoding (poly)peptides having chips activity |
| 07/12/2001 | CA2395803A1 Y-ifn liquid-droplet aerosol and method |
| 07/12/2001 | CA2395636A1 Novel colloid synthetic vectors for gene therapy |
| 07/12/2001 | CA2395625A1 Progenitor cell preservation factors and related methods and products |
| 07/12/2001 | CA2395610A1 Methods and compositions for inhibiting adhesion by microorganisms |
| 07/12/2001 | CA2395487A1 Composition for the treatment of damaged tissue |